Biosecure Act MIA from US defense bill in key win for China biopharma service providers
Fierce Pharma
DECEMBER 9, 2024
Sat.Dec 07, 2024 - Fri.Dec 13, 2024
207 
GSK Multiple Myeloma Drug’s DREAMM Comeback Continues With Phase 3 Data at ASH
MedCity News
DECEMBER 9, 2024
Results from the Phase 3 DREAMM-7 study show GSK drug Blenrep is helping multiple myeloma patients live longer compared to treatment with blockbuster Johnson & Johnson drug Darzalex. The data, presented Monday during the annual meeting of the American Society of Hematology, are part of a submission now under FDA review that could lead to Blenreps return to the market.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Reprieve for Chinese biotechs as BIOSECURE Act left out of key bill
Pharmaceutical Technology
DECEMBER 9, 2024
Shares in WuXi AppTec, one of those implicated in the Chinese biotech blacklisting legislation, surged following the omission.
Imfinzi receives NICE recommendation for lung cancer treatment
PharmaTimes
DECEMBER 9, 2024
Trial results lead to new treatment option for lung cancer
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
The Big 3 PBMs are Countersuing the FTC. Does Their Argument Have Any Teeth?
MedCity News
DECEMBER 8, 2024
After the FTC filed a lawsuit in September, accusing the three major pharmacy benefit managers of anticompetitive rebating practices related to insulin, the defendants reversed roles and became plaintiffs. In November, they countersued the agency, arguing that its lawsuit is unconstitutional. The post The Big 3 PBMs are Countersuing the FTC. Does Their Argument Have Any Teeth?
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
CatalYm shows potential of visugromab for treating cachexia
PharmaTimes
DECEMBER 10, 2024
New findings presented at international SCWD conference
ASH: AstraZeneca proposes fixed-duration Calquence combos in chronic lymphocytic leukemia
Fierce Pharma
DECEMBER 7, 2024
Safety Stands Out in Arcellx Cell Therapy’s ASH Data, But Don’t Overlook Manufacturing Advantages
MedCity News
DECEMBER 10, 2024
Arcellxs cell therapy for multiple myeloma has shown no signs of the parkinsonism complication observed in clinical testing of Carvykti, a rival product from partners Johnson & Johnon and Legend Biotech. Arcellx is developing its CAR T-treatment under a partnership with Gilead Sciences. The post Safety Stands Out in Arcellx Cell Therapys ASH Data, But Dont Overlook Manufacturing Advantages appeared first on MedCity News.
Richard Charkin on South Carolina’s Charleston Conference
Copyright Clearance Center
DECEMBER 9, 2024
Richard Charkin makes his first trip to the Charleston Conference of scholarly librarians and publishers.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy
PharmaTimes
DECEMBER 11, 2024
Promising results set stage for European marketing authorization
Amgen's Blincyto keeps 96% of pediatric leukemia patients alive and disease-free in 'practice changing' 3-year study
Fierce Pharma
DECEMBER 9, 2024
Safety Signal in Phase 2 Deals a Setback to BioAge Labs’ Muscle-Preserving Obesity Drug
MedCity News
DECEMBER 8, 2024
BioAge Labs said the potential safety problem was observed in some who received experimental drug azelaprag, which is being tested as a monotherapy and in combination with Eli Lilly obesity medication Zepbound. No safety signals were observed in those who received Zepbound alone. The post Safety Signal in Phase 2 Deals a Setback to BioAge Labs Muscle-Preserving Obesity Drug appeared first on MedCity News.
GSK’s multiple myeloma ADC Blenrep was pulled from the market. Now, it’s poised for a comeback.
PharmaVoice
DECEMBER 10, 2024
Merck gets rare win with Keytruda-Lynparza combo but role of Keytruda in ovarian cancer 'remains uncertain'
Fierce Pharma
DECEMBER 9, 2024
A Lifetime Guarantee on a Shoulder Implant? This Device Maker Is Offering It Through Geisinger
MedCity News
DECEMBER 9, 2024
Swiss Medtech Company Medacta teamed up with Geisinger to begin providing the world’s first, lifetime guarantee on shoulder replacement surgeries. The post A Lifetime Guarantee on a Shoulder Implant? This Device Maker Is Offering It Through Geisinger appeared first on MedCity News.
Poolbeg Pharma presents positive results for POLB 001
PharmaTimes
DECEMBER 9, 2024
promising pre-clinical data on preventing cytokine release syndrome
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Psychedelics haven’t fulfilled clinical expectations, but new trial strategies could turn the tide
PharmaVoice
DECEMBER 9, 2024
CSL Vifor floats £23M offer, doctor outreach campaign in bid to resolve UK antitrust probe
Fierce Pharma
DECEMBER 10, 2024
Cala Health Snags $50M for At-Home Tremor Relief Therapy
MedCity News
DECEMBER 9, 2024
Cala Health closed a $50 million funding round. The Silicon Valley-based company sells an FDA-cleared wearable device that temporarily relieves hand tremors in people with essential tremor and Parkinsons disease. The post Cala Health Snags $50M for At-Home Tremor Relief Therapy appeared first on MedCity News.
Er-Kim and Ascendis’ endocrine therapy agreement extended in Eurasia
Pharmaceutical Technology
DECEMBER 11, 2024
Er-Kim has extended its exclusive agreement with Ascendis Pharma for endocrinology treatments across multiple countries in Eurasia.
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Lilly CEO Ricks provides hints on how Trump will approach healthcare issues
Fierce Pharma
DECEMBER 11, 2024
More Than 70 Organizations Urge Congress to Extend Enhanced Premium Tax Credits
MedCity News
DECEMBER 10, 2024
In a letter, Families USA and numerous other organizations called on Congress to extend the enhanced premium tax credits that are set to expire at the end of 2025. The post More Than 70 Organizations Urge Congress to Extend Enhanced Premium Tax Credits appeared first on MedCity News.
Meitheal gains US commercial rights for CABP treatment therapy
Pharmaceutical Technology
DECEMBER 12, 2024
Meitheal Pharmaceuticals has gained exclusive US commercial rights for XENLETA for treating CABP in the adult population.
How to Stay Competitive in the Evolving State of Martech
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
iOnctura achieves new clinical milestones in uveal melanoma therapy
PharmaTimes
DECEMBER 11, 2024
Successful phase 1 study highlights potential of roginolisib
With Biktarvy patent cliff ahead, Gilead lays out a plan to keep the HIV crown with 7 launches through 2033
Fierce Pharma
DECEMBER 11, 2024
How AI Can Close the Gap in Evidence-Based Care
MedCity News
DECEMBER 9, 2024
With evidence generated in minutes, the days of broad-based guidelines will be gone, as researchers and clinicians will have personalized evidence at their fingertips that can transform value-based care. The post How AI Can Close the Gap in Evidence-Based Care appeared first on MedCity News.
UK indefinitely bans puberty blockers for teenagers due to “unacceptable risk”
Pharmaceutical Technology
DECEMBER 12, 2024
Puberty blockers for people aged under 18 with gender dysphoria will be indefinitely banned by the UK Government.
Let's personalize your content